BOTHELL, WA, October 15, 2025 — PharmaIN Corporation, a clinical-stage biopharmaceutical company, today announced that the company will present single-ascending dose results from its ongoing Phase 1 clinical trial of PHIN-214, the company’s lead candidate for the outpatient management of portal hypertension and its complications in patients with cirrhosis. Douglas Simonetto, M.D., Mayo Clinic College of Medicine and Science, Rochester, MN, will present the findings at the AASLD The Liver Meeting®, taking place November 7–11, 2025, in Washington, D.C.

PHIN-214 is a novel vasopressin analogue with partial V1a receptor agonism, reduced V2 activity, and a wide therapeutic index designed to induce splanchnic vasoconstriction that reduces portal pressure while minimizing the risk of severe side effects associated with traditional therapies.

Presentation Details:

Abstract Title: PHASE 1, SINGLE-ASCENDING DOSE RESULTS FROM THE PHIN-001 STUDY OF PHIN-214 IN COMPENSATED AND DECOMPENSATED PATIENTS WITH CIRRHOSIS

Authors: Douglas A. Simonetto¹, Naim Alkhouri², Ethan Weinberg³, Christina C. Lindenmeyer⁴, Gary Reiss⁵, Eric Lawitz⁶

¹Mayo Clinic Rochester,²Arizona Liver Health,³University of Pennsylvania,⁴Cleveland Clinic Foundation,⁵Tandem Research,⁶Texas Liver Institute, University of Texas Health San Antonio

Abstract Number: 2404

Session: Poster, Portal Hypertension and Other Complications of Cirrhosis (2280-2479)

Date & time: Saturday 8^th November 2025, 8 a.m.-5 p.m. EST (presentation time: 1-2 p.m. EST)

Location: Hall DE (Posters & Exhibits)

Abstract titles are now available on the AASLD website. The poster will be made available on the PharmaIN website following presentation at the conference.

About PHIN-214:
PHIN-214 is an optimized vasopressor therapy designed to target a clinically validated mechanism of action in portal hypertension. Presented as a convenient subcutaneous injection, PHIN-214 offers a potentially safer and more practical treatment option for management of complications associated with portal hypertension in patients with advanced cirrhosis.   

PharmaIN is currently enrolling patients for the multiple ascending dose part of its Phase 1 clinical trial evaluating PHIN-214 (NCT05490888).

About PharmaIN:
PharmaIN Corporation, based in Bothell, WA, is a clinical-stage biopharmaceutical company pioneering first- and best-in-class subcutaneous therapies through thoughtful peptide engineering. By leveraging its expertise in target-specific biology, peptide drug design, and innovative drug delivery, PharmaIN is focused on developing novel treatments for patients with advanced cirrhosis and cancer. Visit our website at www.pharmain.com.

FOR FURTHER INFORMATION, PLEASE CONTACT: BD@pharmain.com